These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

910 related items for PubMed ID: 17339618

  • 1. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
    Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, Treatment of Osteoporosis with Parathyroid Hormone Study Group.
    Ann Intern Med; 2007 Mar 06; 146(5):326-39. PubMed ID: 17339618
    [Abstract] [Full Text] [Related]

  • 2. Summaries for patients. Parathyroid hormone (1-84) and risk for spinal fractures in women with osteoporosis.
    Ann Intern Med; 2007 Mar 06; 146(5):I20. PubMed ID: 17339614
    [No Abstract] [Full Text] [Related]

  • 3. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, ACTIVE Study Investigators.
    JAMA; 2016 Aug 16; 316(7):722-33. PubMed ID: 27533157
    [Abstract] [Full Text] [Related]

  • 4. Recombinant full-length parathyroid hormone (1-84).
    Moen MD, Scott LJ.
    Drugs; 2006 Aug 16; 66(18):2371-81; discussion 2382-5. PubMed ID: 17181378
    [Abstract] [Full Text] [Related]

  • 5. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D.
    J Clin Endocrinol Metab; 1997 Feb 16; 82(2):620-8. PubMed ID: 9024265
    [Abstract] [Full Text] [Related]

  • 6. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH.
    N Engl J Med; 2001 May 10; 344(19):1434-41. PubMed ID: 11346808
    [Abstract] [Full Text] [Related]

  • 7. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS, LOFT Investigators.
    Lancet Diabetes Endocrinol; 2019 Dec 10; 7(12):899-911. PubMed ID: 31676222
    [Abstract] [Full Text] [Related]

  • 8. Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36 months: treatment extension study.
    Zanchetta JR, Bogado CE, Cisari C, Aslanidis S, Greisen H, Fox J, Lems W.
    Curr Med Res Opin; 2010 Nov 10; 26(11):2627-33. PubMed ID: 20923256
    [Abstract] [Full Text] [Related]

  • 9. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD.
    JAMA; 1999 Oct 13; 282(14):1344-52. PubMed ID: 10527181
    [Abstract] [Full Text] [Related]

  • 10. Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy.
    Fogelman I, Fordham JN, Fraser WD, Spector TD, Christiansen C, Morris SA, Fox J.
    Calcif Tissue Int; 2008 Aug 13; 83(2):85-92. PubMed ID: 18626566
    [Abstract] [Full Text] [Related]

  • 11. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
    Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F.
    Lancet; 1997 Aug 23; 350(9077):550-5. PubMed ID: 9284777
    [Abstract] [Full Text] [Related]

  • 12. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA.
    J Bone Miner Res; 2004 May 23; 19(5):728-36. PubMed ID: 15068495
    [Abstract] [Full Text] [Related]

  • 13. Incidence of hypercalcemia, hypercalciuria and related factors in patients treated with recombinant human parathyroid hormone (1-84).
    Luna-Cabrera F, Justicia-Rull EA, Caricol-Pérez MP, Soler-Vizán E, Mesa-López CM, Ruiz-Ruiz MA, De La Torre-López LE.
    Minerva Med; 2012 Apr 23; 103(2):103-10. PubMed ID: 22513515
    [Abstract] [Full Text] [Related]

  • 14. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR.
    JAMA; 1999 Aug 18; 282(7):637-45. PubMed ID: 10517716
    [Abstract] [Full Text] [Related]

  • 15. Use of recombinant human parathyroid hormone(1-84) in patients with postmenopausal osteoporosis: a prospective, open-label, single-arm, multicentre, observational cohort study of the effects of treatment on quality of life and pain--the PROPOSE study.
    Möricke R, Rettig K, Bethke TD.
    Clin Drug Investig; 2011 Aug 18; 31(2):87-99. PubMed ID: 21155613
    [Abstract] [Full Text] [Related]

  • 16. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
    Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY.
    N Engl J Med; 2004 Jan 29; 350(5):459-68. PubMed ID: 14749454
    [Abstract] [Full Text] [Related]

  • 17. Full length parathyroid hormone, PTH(1-84), for the treatment of severe osteoporosis in postmenopausal women.
    Adami S.
    Curr Med Res Opin; 2008 Nov 29; 24(11):3259-74. PubMed ID: 18940041
    [Abstract] [Full Text] [Related]

  • 18. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
    Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ.
    J Clin Endocrinol Metab; 2000 Jun 29; 85(6):2129-34. PubMed ID: 10852440
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.